Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172005 | 0.85 | PDK2 (0.43) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1170641 | 0.83 | PDK2 (0.42) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1172017 | 0.83 | PDK2 (0.47) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171305 | 0.82 | PDK2 (0.46) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171690 | 0.82 | GPR119 (0.46) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171423 | 0.81 | GPR119 (0.54) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171664 | 0.81 | GPR119 (0.46) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171293 | 0.81 | GPR119 (0.59) | PDK2GPR119 | |
| SCHEMBL1171162 | 0.81 | GPR119 (0.47) | PDK2MAPTNR1H2GRM1GRM5 | |
| SCHEMBL1171255 | 0.80 | PDK2 (0.44) | PDK2MAPTGRM1GRM5GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888347-B2 | e.g. 1-(Phenylmethyl)hexahydro-4H-azepin-4-one hydrochloride; neurological and psychiatric disorders; neurodegenerative diseases, cognitive impairments, antiinflammatory agent; Alzheimer's disease, epilepsy, neuritis and back pain, osteoarthritis, rheumatoid arthritis, migraine, Parkinson's disease | GLAXO GROUP LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| EP-1899350-B1 | PYRAZOLO [3 , 4-D]AZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-05-12 | — | — | EP | disclosed |
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176832-A1 | Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | PDK2 558/4885MAPT 463/4885NR1H2 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.